Clinical Trials

40 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Active not recruiting

100 enrolled

Breast

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT06744075 2025-12-30

CELERITY

108 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Neoplasm, Residual

NCT07178847 2025-12-01

NeckTAR-IN

59 enrolled

Neoplasm, Residual

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

120 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07003737 2025-06-04

Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

LymphoidOther hematologic neoplasm

114 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06930807 2025-04-16

Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer

1,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT06885476 2025-03-20

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

22 enrolled

Phase NA Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06763302 2025-01-08

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

1,220 enrolled

Neoplasm, Residual

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

100 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT05117879 2024-10-17

R0 Resection Rate Between CSP, cEMR and hEMR for 1-2 cm Colorectal SSLs

120 enrolled

Neoplasm, Residual

NCT06301425 2024-07-10

MRD Response-adapted Allo-HSCT for Adverse-risk AML

178 enrolled

Phase NA Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06090786 2024-04-10

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

225 enrolled

Phase NA Active not recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05697913 2024-03-06

Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation

66 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT06066905 2023-10-27

A Study of Chidamide With AZA in MRD Positive AML After Transplant

60 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05093192 2023-09-08

Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia

LymphoidOther hematologic neoplasm

26 enrolled

Motor Activity, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT05956977 2023-07-24

Neuro3DUS

Phase NA Unknown

90 enrolled

Neoplasm, Residual

NCT03189576 2023-05-26

Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Phase NA Unknown

37 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT05603156 2022-11-02

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Phase NA Unknown

46 enrolled

Neoplasm, Residual

NCT04179929 2022-02-18

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

LymphoidOther hematologic neoplasm

300 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01594892 2019-09-04

DOSIS

60 enrolled

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplastic Processes, Pain, Neoplasm, Residual

NCT02339805 2017-07-07

LymphoSeq

30 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm, Residual

NCT02900950 2016-09-15

MPM